Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 12/20 | 0.94 |
| ▸ | HTT | P42858 | 2/20 | 0.94 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.79 |
| ▸ | RAD52 | P43351 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.64 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL8894051 | 1.00 | DNM1 (0.94) | DNM1HTTHSP90AA1RAD52KMT2A | |
| Bromide SCHEMBL5547871 | 1.00 | DNM1 (0.94) | DNM1HTTHSP90AA1RAD52KMT2A | |
| Bromide SCHEMBL5088590 | 1.00 | DNM1 (0.94) | DNM1HTTHSP90AA1RAD52KMT2A | |
| Bromide SCHEMBL668957 | 1.00 | DNM1 (0.94) | DNM1HTTHSP90AA1RAD52KMT2A | |
| Bromide SCHEMBL1318093 | 1.00 | DNM1 (0.94) | DNM1HTTHSP90AA1RAD52KMT2A | |
| Bromide SCHEMBL9179827 | 1.00 | DNM1 (0.94) | DNM1HTTHSP90AA1RAD52KMT2A | |
| Bromide SCHEMBL22397860 | 1.00 | DNM1 (0.94) | DNM1HTTHSP90AA1RAD52KMT2A | |
| Bromide SCHEMBL22397869 | 1.00 | DNM1 (0.94) | DNM1HTTHSP90AA1RAD52KMT2A | |
| Bromide SCHEMBL21986903 | 1.00 | DNM1 (0.94) | DNM1HTTHSP90AA1RAD52KMT2A | |
| Bromide SCHEMBL9172996 | 1.00 | DNM1 (0.94) | DNM1HTTHSP90AA1RAD52KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 467 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746853-A1 | A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2026-05-27 | — | — | EP | claimed |
| CN-115746353-B | Preparation method and application of multifunctional polyethylene film | 万华化学集团股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-117623327-B | Ni modified micropore-mesoporous molecular sieve and preparation method and application thereof | 万华化学集团股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-12492339-B2 | Quantum dot film, quantum dot light-emitting diode and preparation method thereof | TCL TECHNOLOGY GROUP CORPORATION (CN) | 2025-12-09 | — | — | US | claimed |
| WO-2025021835-A9 | A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-11-06 | — | — | WO | claimed |
| CN-111718716-B | Nanostructure with inorganic ligands for electroluminescent devices | 昭荣化学工业株式会社 | 2025-06-10 | — | — | CN | claimed |
| CN-120059018-A | High-Wen Chaozhi-resistant polymer tackifier for composite calcium salt water completion fluid and preparation method and application thereof | 中国石油大学(华东) | 2025-05-30 | — | — | CN | claimed |
| CN-116162033-B | Oligomeric surfactant, preparation method thereof and application of oligomeric surfactant as targeted deposition herbicide adjuvant | 中国科学院化学研究所 | 2025-05-06 | — | — | CN | claimed |
| EP-4527499-A1 | A CATALYST FOR HYDROGENATION OF UNSATURATED HYDROCARBONS AND A METHOD FOR PREPARATION THEREOF | Indian Oil Corporation Limited (IN) | 2025-03-26 | — | — | EP | claimed |
| US-20250091037-A1 | CATALYST FOR HYDROGENATION OF UNSATURATED HYDROCARBONS AND A METHOD FOR PREPARATION THEREOF | INDIAN OIL CORPORATION LIMITED (IN) | 2025-03-20 | — | — | US | claimed |
| WO-2012057702-A1 | METHOD OF PREPARING A POROUS GRAPHENE FILM | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-05-03 | — | — | WO | claimed |
| WO-2012009684-A2 | DRUG DELIVERY MEDICAL DEVICE | MICELL TECHNOLOGIES, INC. (US) | 2012-01-19 | — | — | WO | claimed |
| CN-102292069-A | Vesicular formulations | — | 2011-12-21 | — | — | CN | claimed |
| WO-2011041377-A1 | OCULAR IONTOPHORESIS OF CHARGED MICELLES CONTAINING BIOACTIVE AGENTS | EYEGATE PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | claimed |
| EP-1606246-B1 | METHOD FOR PRODUCING 2-CYAN-3-HYDROXY-N-(PHENYL)BUT-2-ENE AMIDES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-05-19 | — | — | EP | claimed |
| US-20100055684-A1 | COMPOSITION FOR NUCLEIC ACID TRANSFECTION | HOKKAIDO SYSTEM SCIENCE CO., LTD. (JP) | 2010-03-04 | — | — | US | claimed |
| EP-1606246-A1 | METHOD FOR PRODUCING 2-CYAN-3-HYDROXY-N-(PHENYL)BUT-2-ENE AMIDES | Sanofi-Aventis Deutschland GmbH (DE) | 2005-12-21 | — | — | EP | claimed |
| US-20050008687-A1 | Metal-porphyrin-complex-embedded liposomes, production process thereof, and medicines making use of the same | MAKOTO YUASA (JP) | 2005-01-13 | — | — | US | claimed |
| WO-2004083165-A1 | METHOD FOR PRODUCING 2-CYAN-3-HYDROXY-N-(PHENYL)BUT-2-ENE AMIDES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-09-30 | — | — | WO | claimed |
| US-6773822-B2 | ANTIFUNGAL AGENT MAY BE PRESENT IN THE GYPSUM CORE AND/OR ON ONE OR BOTH OF THE PAPER FACINGS, AND MAY BE ENCAPSULATED IN A MATERIAL THAT RELEASES THE ANTIFUNGAL AGENT OVER TIME AND/OR UPON EXPOSURE TO MOISTURE. | TEMPLE-INLAND FOREST PRODUCTS CORPORATION | 2004-08-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008687-A1 | Metal-porphyrin-complex-embedded liposomes, production process thereof, and medicines making use of the same | GPX4, FECH, PPOX | DNM1 732/4885HTT 3240/4885HSP90AA1 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.